Binding of EGF peptide and EGF receptor antibodies and its fragments in different tumor models

Hybridoma

Volumn 18, Issue 1, 1999, Pages 29-35

  Senekowitsch Schmidtke, R ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IODINE 125; MONOCLONAL ANTIBODY 425; PROTEIN TYROSINE KINASE; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING COMPETITION; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER MODEL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; INCUBATION TIME; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; TUMOR DIFFERENTIATION;

ANIMALIA;

EID: 0032998460     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.29     Document Type: Conference Paper

References (26)

1. Ullrich A, and Schlesinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
2. Ethier SP: Growth factor synthesis and human breast cancer progression. J Natl Cancer Inst 1995;87:964-973.
3. Gullick WJ: The role of epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer 1990;5:55-61.
4. Yano H, Shiozaki H, Kobayashi K, et al.: Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer 1991;64:91-98.
5. Wataru Y, Hiromichi S, Jotaro H, et al.: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137-141.
6. Torp SH, Helseth E, Dalen A, and Unsgaard G: Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother 1991;33:61-64.
7. Teramoto T, Onda M, Tokunaga A, and Asano G: Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer 1996;77:1639-1645.
8. Modjahedi H, and Dean C: The receptor for EGF and ist ligands: Expression, prognostic value and target for therapy in cancer (review). Int J Oncol 1994;4:277-296.
9. Ennis BW, Lippman ME, and Dickson RB: The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991;9: 553-562.
10. Divgi CR, Welt S, Kris M, et al.: Phase I and imaging trial of indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody 425 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97-104.
11. Goldenberg A, Masiu H, Divgi C, Kamrath H, Pentlow K, and Mendelsohn J: Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 1989;18:1616-1625.
12. Rodeck U, Herlyn M, Herlyn D, et al.: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effect. Cancer Res 1987;47:3692-3696.
13. Takahashi H, Herlyn D, Atkinson B, et al.: Radoimmunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor. Cancer 1987;47:3847-3850.
14. Emrich JG, Bender H, Class R, Eshleman J, Miyamoto C, and Brady LW: In vitro evaluation of Iodine-125-labeled monoclonal antibody (Mab 425) in human high-grade glioma cells. Am J Clin Oncol (CCT) 1996;19:601-608.
15. Schnürch H-G, Stegmüller M, Vering A, Beckmann MW, and Bender HG: Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor. Eur J Cancer 1994;30a:491-496.
16. 125I-labeled Monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992;52:121-126.
17. Wersäll P, Ohlsson I, Biberfeld P, Collins VP, von Krustenstjerna S, Larsson S, Mellstedt H, and Boethius J: Intratumoral infusion of the monoclonal antibody, MAb 425, against the epidermal growth factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 1997;44:157-164.
18. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, and Harris AL: The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29:41-49.
19. Nußbaumer J, Gunsenheimer B, Haunschild J, Steiner K, and Senekowitsch R: Anti-EGF-receptor Mab 425 has a growth-inhibiting influence on tumor cells and leads to a differentiation of multicell tumor spheroids. In: Current Tumor Diagnosis: Application, Clinical Relevance, Research Trends. Klapdor R (Ed.). Zuckschwerdt Verlag, München, 1994, pp. 776-779.
20. Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, and Weinstein JN: Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier. Proc Natl Acad Sci USA 1995;92:8999-9003.
21. Cobb LM: Intratumoral factors influencing the access of antibody to tumor cells. Cancer Immunol Immunother 1989;28:235-240.
22. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(Suppl.):814s-819s.
23. Gabler B, Aicher T, Heiss P, and Senekowitsch-Schmidtke R: Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 1997;17:3157-3160.
24. Senekowitsch-Schmidtke R, Steiner K, Haumschild J, Möllenstädt S, and Truckenbrodt R: In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF ans anti-(EGF receptor) mAb 425. Cancer Immunol Immunother 1996;42:108-114.
25. Haunschild J, Steiner K, Faro HP, and Senekowitsch R: Pharmakokinetics of reshaped MAb 425 in three animal species. Cell Biophys 1995;26:167-182.
26. Steiner K, Haunschild J, Faro H-P, and Senekowitsch R: Distribution of humanized MAb425 (EMD 62 000) in rats and specific localization in tumor-bearing nuce mice. Cell Mol Biol 1995;41: 179-184.